Biogen has appointed Michael Ehlers as executive vice president of research and development. He will report to CEO George Scangos and will begin his tenure in late May. Ehlers joins Biogen from Pfizer where he served as group senior vice president for biotherapeutics research and development and CSO for the company's Neuroscience and Pain Research Unit. Prior to joining Pfizer in 2010, he was a professor of neurobiology and an investigator at the Howard Hughes Medical Institute at Duke University Medical Center.
Ardy Arianpour has joined BaseHealth as the company's chief business officer.
Arianpour has over 14 years of experience in the genomics market. Prior to joining BaseHealth, he was chief commercial officer at Pathway Genomics. Before that, he held senior executive roles at Ambry Genetics and Cogenics. He also sits on advisory boards for Vitagene and Celmatix and is founder and managing partner for Octyne.
Arianpour has a BS in biology from the University of California, Irvine, and an MBA in strategic management from Marshall Goldsmith School of Management.
Natera said that Kimberly Martin has assumed a new role in the company as senior global medical director of Natera's women's health franchise. She previously served as the firm's medical director for reproductive testing.
Martin has more than 20 years of prenatal diagnosis, ultrasound, and genetic counseling experience practicing in both academic and community-based healthcare settings. She received her medical degree from McGill University in Montreal, Canada and completed her residency in Obstetrics and Gynecology at the University of Western Ontario in London, Canada, as well as a fellowship in Clinical Genetics at the University of British Columbia in Vancouver, Canada. She is board certified in both obstetrics and gynecology and clinical genetics in Canada and the US.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.